On Monday, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule requiring drug manufacturers to list a product’s monthly wholesale price, or the cost for a typical course of treatment, if it is greater than $35 for 30 days. CMS asserts that the purpose of the proposed rule is to reduce drug prices overall.
Read full ACG blog here:
http://acgblog.org/2018/10/19/new-cms-rule-drug-advertisements-must-include-list-prices/